EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Huperzine A suppresses absence seizures in the genetic absence epilepsy rat from Strasbourg ( GAERS ) model of genetic generalized epilepsy with absence seizures

Pablo M Casillas-Espinosa iD, Jennie Garcia-Olivares iD, Rui Li, Crystal Li, Chungping Yu, Andrea E Formella, Terence J O'Brien

Epilepsia Open · 2024

DOI: 10.1002/epi4.13016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia Open, 2024. Verfasst von Pablo M Casillas-Espinosa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Alkaloids, Epilepsy, Absence, Disease Models, Animal, Anticonvulsants. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We evaluated huperzine A treatment in the Genetic Absence Epilepsy Rat from Strasbourg (GAERS) model of genetic generalized epilepsy (GGE) with absence seizures.

Methods

Adult male GAERS ( N = 15) were implanted with EEG recording electrodes 10 days before receiving study drug. Each animal received the following six treatments as a single, intraperitoneal dose, 7 days apart (in random order): huperzine A (0.3, 1.0, or 3.0 mg/kg), two periods of vehicle (0.9% NaCl), or ethosuximide (100 mg/kg) as a positive control. Electroencephalograms (EEGs) were acquired for 24 h before and after each treatment and analyzed for seizure activity during the 90‐min period immediately post‐treatment, including 30‐min intervals at 30, 60, and 90 min. Additional analyses evaluated seizure activity over the 24‐h post‐treatment period using 60‐min intervals at 6, 12, and 24 h. The cumulative 24‐h periods before and after each administered treatment were also compared.

Results

Two‐way ANOVA showed a treatment difference [ F (91,182) = 3.592, p < 0.0001] on the number of seizures over the first 90‐min post‐treatment (primary outcome); Tukey's post hoc analyses showed that, compared to vehicle, huperzine A (3.0 mg/kg) significantly reduced seizures in the 30‐min ( p = 0.02) and 60‐min ( p = 0.001) intervals, and ethosuximide significantly reduced seizures at all measured time intervals except the 1‐h blocks at 12 and 24 h. Huperzine A 3.0 mg/kg and ethosuximide significantly reduced seizures during the cumulative 24‐h post‐treatment period relative to pretreatment baseline. While huperzine A 3.0 mg/kg did not differ significantly from ethosuximide at any time point, the study was not designed to evaluate non‐inferiority. The only adverse event after huperzine A or ethosuximide was mild, dose‐dependent sedation. Significance Huperzine A potently suppressed absence‐like seizures in GAERS, albeit with a shorter duration of action relative to ethosuximide, showing promise for clinical efficacy in GGE. Plain Language Summary This study looked at how huperzine A affects seizures in rats with similar abnormal brain activity as seen in humans with absence epilepsy. Rats received different treatments, placebo (i.e., saline solution), huperzine A, and ethosuximide. Ethosuximide is considered a gold standard treatment for absence epilepsy. We recorded brain activity to measure seizures before and after each treatment. We found that huperzine A (3.0 mg/kg) reduced seizures soon after treatment, like ethosuximide. Both treatments appeared safe, causing only mild sleepiness. The study shows that huperzine A could be a good new treatment for a type of absence epilepsy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlkaloidsEpilepsy, AbsenceDisease Models, AnimalAnticonvulsantsElectroencephalographySesquiterpenesEthosuximideAnimalsRatsMaleEpilepsy, GeneralizedDose-Response Relationship, DrugSeizures

Stichwörter der Autor:innen

GAERS modelSPN‐817crossover studyethosuximideidiopathic generalized epilepsyspike–wave discharges

Substanzen

Alkaloidshuperzine AAnticonvulsantsSesquiterpenesEthosuximide

Autor:innen und Institutionen

  • Department of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia.
  • Department of Neuroscience, School of Translational Medicine,, Monash University, Melbourne, Victoria, Australia.
  • Department of Neurology, The Alfred Hospital, Melbourne, Victoria, Australia.
  • Supernus Pharmaceuticals, Inc., Rockville, Maryland, USA.

ORCID-Profile: Pablo M Casillas-Espinosa, Jennie Garcia-Olivares

Zitieren

APA

Casillas-Espinosa, P. M., Garcia-Olivares, J., Li, R., Li, C., Yu, C., Formella, A. E., & O'Brien, T. J. (2024). Huperzine A suppresses absence seizures in the genetic absence epilepsy rat from Strasbourg ( GAERS ) model of genetic generalized epilepsy with absence seizures. Epilepsia Open. https://doi.org/10.1002/epi4.13016

Vancouver

Casillas-Espinosa PM, Garcia-Olivares J, Li R, Li C, Yu C, Formella AE, et al. Huperzine A suppresses absence seizures in the genetic absence epilepsy rat from Strasbourg ( GAERS ) model of genetic generalized epilepsy with absence seizures. Epilepsia Open. 2024. doi:10.1002/epi4.13016

BibTeX
@article{CasillasEspinosa2024,
  author = {Casillas-Espinosa, Pablo M and Garcia-Olivares, Jennie and Li, Rui and Li, Crystal and Yu, Chungping and Formella, Andrea E and O'Brien, Terence J},
  title = {Huperzine A suppresses absence seizures in the genetic absence epilepsy rat from Strasbourg ( GAERS ) model of genetic generalized epilepsy with absence seizures},
  journal = {Epilepsia Open},
  year = {2024},
  doi = {10.1002/epi4.13016}
}
Kostenlos starten →